

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

September 13, 2024

Claire Mazumdar, Ph.D., M.B.A. Chief Executive Officer Bicara Therapeutics Inc. 116 Huntington Avenue, Suite 703 Boston, MA 02116

> Re: Bicara Therapeutics Inc. Registration Statement on Form S-1 Exhibit Nos. 10.9 and 10.10 Filed August 22, 2024 File No. 333-281722

Dear Dr. Claire Mazumdar:

We have concluded our assessment of your redacted exhibits for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Gabriela Morales-Rivera, Esq.